| RMD |
Report |
Q4 FY2026 revenue |
IN-LINE |
pred ~$1.475B vs. cons $1.466B |
MEDIUM |
| RMD |
Report |
Q4 FY2026 non-GAAP diluted EPS |
BEAT |
pred ~$2.92 vs. cons $2.88 |
MEDIUM |
| RMD |
Report |
Q4 FY2026 non-GAAP gross margin |
IN-LINE |
pred ~62.9% vs. cons 62.8% |
MEDIUM |
| RMD |
Guide |
FY2027 reported revenue outlook, including MatrixCare divestiture and Noctrix |
BETTER |
guide ~$5.95B vs. cons $5.89B (FY2027) |
MEDIUM |
| RMD |
Guide |
FY2027 non-GAAP diluted EPS outlook |
BETTER |
guide ~$12.15 vs. cons $12.03 (FY2027) |
MEDIUM |
| RMD |
Guide |
FY2027 non-GAAP gross-margin outlook |
BETTER |
guide ~63.1% vs. cons 62.8% (FY2027) |
MEDIUM |
| RMD |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| RMD |
Return |
5-day cumulative residual |
+4.5% (FOLLOW-THROUGH) |
A ~1.4% EPS beat versus consensus and FY2027 EPS guide of ~$12.15 versus ~$12.03 support upward out-period revisions despite the ~$0.20 Noctrix dilution and MatrixCare revenue removal. |
MEDIUM |